-
Product Insights
Pleural Disease - Drugs In Development, 2024
Empower your strategies with our Pleural Disease – Drugs In Development, 2024 report and make more profitable business decisions. Pleural disorders encompass a spectrum of conditions affecting the protective tissue surrounding the lungs and lining the chest cavity. Within this category, three distinct types emerge—namely pleurisy, pleural effusion, and pneumothorax—each with diverse etiologies. Characterized by inflammation of the pleura, pleurisy stands as a primary manifestation. Conversely, pleural effusion and pneumothorax result from factors such as infection, medical conditions, or chest trauma,...
-
Product Insights
Pulmonary Inflammation - Drugs In Development, 2024
Empower your strategies with our Pulmonary Inflammation – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary Inflammation also called Pnemonia is an infection that inflames air sacs in one or both lungs, which may fill with fluid. Lung inflammation is favored by the combined action of oxidative stress, ACPA and Th17 cells. Widespread of pulmonary inflammation causes increased permeability of the alveolar capillary membrane leading to flooding and collapse of alveoli and severely impaired gas exchange. Pulmonary...
-
Product Insights
Community-Acquired Bacterial Pneumonia - Drugs In Development, 2024
Empower your strategies with our Community-Acquired Bacterial Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia is defined as pneumonia that is acquired outside the hospital. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, atypical bacteria (ie, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella species), and viruses. Symptoms and signs are fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia The Community-Acquired Bacterial Pneumonia drugs in development market research report provide comprehensive information...
-
Product Insights
Bronchiolitis - Drugs In Development, 2024
Empower your strategies with our Bronchiolitis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchiolitis is inflammation of the small airways in the lungs. It is the most common lower respiratory tract infection in pediatric patients between 1 month and 2 years of age. It is usually caused by the respiratory syncytial virus (RSV) and is characterized by inflammation, edema, and necrosis of the bronchiole's epithelium. It is transmitted by air droplets. symptoms of bronchiolitis include fever,...
-
Product Insights
Perennial Allergic Rhinitis - Drugs In Development, 2024
Empower your strategies with our Perennial Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Perennial rhinitis is an inflammatory condition that causes nasal congestion and runny nose. It is of two types: perennial allergic rhinitis and non-allergic rhinitis. Dust mites, pet dander, and mold are the most common allergens respoinsible for allergic rhinitis. Physical examination, blood or skin testing, and CT scan can be used for diagnosis. Management includes allergen avoidance along with pharmacological treatment....
-
Product Insights
Acute Respiratory Failure - Drugs In Development, 2024
Empower your strategies with our Acute Respiratory Failure – Drugs In Development, 2024 report and make more profitable business decisions. Acute respiratory failure is when lungs become suddenly unable to provide enough oxygen to the blood. Symptoms of respiratory failure include shortness of breath, tachypnea, extreme tiredness, heart palpitations, restlessness, and pale skin. It can be caused by insufficient blood flow to the lungs; blockage, scarring, or fluid in the lungs; or inability to breathe. It can be diagnosed by testing...
-
Product Insights
Pleural Effusion - Drugs In Development, 2024
Empower your strategies with our Pleural Effusion – Drugs In Development, 2024 report and make more profitable business decisions. Pleural Effusion also known as fluid in lungs is a condition where accumulation of fluid in pleural space of lungs observed. Underlying disease conditions of the lungs like pneumonia, emphysema, TB, etc, and other conditions like CKD, heart failure, and pancreatitis can also cause pleural effusion, and sometimes the etiology is unknown. It is usually classified as transudates and exudates. Normal pleural...
-
Product Insights
Emphysema - Drugs In Development, 2024
Empower your strategies with our Emphysema – Drugs In Development, 2024 report and make more profitable business decisions. Emphysema is a form of chronic obstructive pulmonary disease (COPD) that affects the air spaces distal to the terminal bronchiole, causing gradual damage to the tissue of the alveoli, reducing alveoli surface area and limiting the flow of oxygen. In emphysema, the walls between many of the air sacs in the lungs are damaged, which causes the air sacs to lose their shape...
-
Product Insights
Malignant Pleural Effusion - Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Effusion – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions. The Malignant Pleural Effusion drugs in development market research report provide comprehensive...
-
Product Insights
Interstitial Lung Fibrosis - Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.